🇺🇸 FDA
Pipeline program

9-ING-41

21-384

Phase 2 small_molecule active

Quick answer

9-ING-41 for Salivary Gland Cancer is a Phase 2 program (small_molecule) at ACTUATE THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
ACTUATE THERAPEUTICS, INC.
Indication
Salivary Gland Cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials